accredited [150:<100,000/mm 3 ). 1 Intracranial neoplasm. 1 Arteriovenous malformation or aneurysm. 1 Use of IV dextran prior to or during PCI. 1 Presumed or documented history of vasculitis. 1 Known hypersensitivity to any ingredient in the formulation or to murine proteins. 1 9 Warnings/Precautions Warnings Hematologic Effects Risk of major bleeding (e.g., intracranial hemorrhage, genitourinary or GI bleeding, bleeding at arterial access site) and minor bleeding (e.g., spontaneous gross hematuria, spontaneous hematemesis); may require blood or platelet transfusions. 1 2 4 5 (See Bleeding Precautions and see Laboratory Monitoring under Cautions.) Pulmonary alveolar hemorrhage reported rarely. 1 Increased risk of major bleeding observed in patients weighing 75 kg; 1 4 5 during concomitant thrombolytic therapy; 1 when PCI is performed within 12 hours of onset of symptoms of MI; 1 following prolonged (> 70 minutes) PCI; 1 or following failed PCI. 1 9 If bleeding cannot be controlled by pressure, discontinue abciximab and concomitant heparin immediately. 1 Sensitivity Reactions Hypersensitivity Reactions Possible anaphylaxis. 1 If anaphylaxis occurs, discontinue abciximab immediately and initiate appropriate treatment; drugs for treatment of hypersensitivity reactions (e.g., epinephrine, dopamine, theophylline, antihistamines, corticosteroids) should be immediately available. 1 Formation of human antichimeric antibody (HACA) reported. 1 3 8 16 22 23 54 63 65 Possible hypersensitivity reactions (including anaphylaxis), thrombocytopenia, or diminished antithrombotic effect if abciximab is readministered or if monoclonal antibodies are administered in patients with HACA titers. 1 General Precautions Bleeding Precautions To reduce risk of bleeding, adhere to strict anticoagulation guidelines; use a short course of low-dose, weight-adjusted heparin; avoid vascular and other trauma; carefully manage vascular (e.g., femoral artery) access site; and monitor all potential bleeding sites during and following treatment. 1 44 60 Use caution in the placement, maintenance, and removal of vascular access sheath; avoid femoral vein sheath placement. 1 When inserting sheath, puncture only anterior wall of femoral artery; avoid Seldinger (through and through) technique. 1 Observe appropriate precautions while sheath is in place (e.g., complete bed rest, elevation of head 30 , restrain limb in which sheath is inserted, frequent monitoring of vascular access site and distal pulse in the involved limb). 1 Following PCI, discontinue heparin immediately; remove arterial sheath within 6 hours following PCI (at least 2 hours after discontinuation of heparin) if aPTT 50 seconds or ACT 175 seconds. 1 Following sheath removal, apply pressure to femoral artery for at least 30 minutes to achieve hemostasis. 1 Measure and monitor hematomas for enlargement. 1 To avoid vascular and other trauma, minimize arterial or venous punctures, IM injections, cutdown sites, and use of nasotracheal intubation, nasogastric tubes, urinary catheters, and automatic BP cuffs; avoid establishment of IV access at noncompressible sites (e.g., subclavian or jugular veins); consider using an indwelling venipuncture device (e.g., heparin lock) for drawing blood; document and monitor vascular puncture sites; and remove dressings gently and carefully. 1 If emergency surgery is needed, discontinue abciximab. 1 Thrombocytopenia Risk of thrombocytopenia. 1 Severe thrombocytopenia (platelet count <20,000/mm 3 ) 19 46 66 reported more frequently than with tirofiban. 1 32 54 67 68 Determine platelet count prior to treatment, at 2 4 hours following initial IV injection, and at 24 hours following initiation of therapy or prior to discharge, whichever occurs first. 1 9 Consider possibility of pseudothrombocytopenia or heparin-induced thrombocytopenia (in patients receiving concomitant heparin therapy). 1 14 47 54 59 70 Exclude pseudothrombocytopenia caused by an in vitro anticoagulant interaction by sampling blood in tubes containing edetate disodium (EDTA), citrate, or heparin. 1 A low platelet count in the presence of EDTA but not in the presence of heparin and/or citrate supports of a diagnosis of pseudothrombocytopenia. 1 If true thrombocytopenia is verified, discontinue abciximab and initiate appropriate treatment and monitoring. 1 Platelet transfusions may partially restore platelet function. 1 Possible increased incidence and severity of thrombocytopenia following readministration. 1 Contraindicated in patients with platelet counts> <100,000/mm 3 . 1 Laboratory Monitoring Prior to administration, obtain platelet count, PT, ACT, and aPTT. 1 Monitor platelet count during and after treatment. 1 (See Thrombocytopenia under Cautions.) When abciximab is initiated 18 24 hours prior to PCI, maintain aPTT between 60 85 seconds. 1 During PCI, maintain ACT 200 seconds. 1 10 12 16 19 45 46 77 If anticoagulation is continued following PCI, maintain aPTT between 55 75 seconds. 1 Monitor aPTT or ACT prior to arterial sheath removal; do not remove sheath unless aPTT 50 seconds or ACT is 150 180 seconds (approximately 6 hours after PCI). 1 Specific Populations Pregnancy Category C. 1 Lactation Not known whether abciximab is distributed into milk. 1 Use with caution. 1 9 Pediatric Use Safety and efficacy not established in children> <18 years of age. 1 9 Geriatric Use No substantial differences in safety and efficacy in patients 65 74 years of age relative to younger adults. 1 Insufficient experience in patients 75 years of age to determine whether these patients respond differently than younger adults. 1 Common Adverse Effects Bleeding, back pain, hypotension, nausea, chest pain, vomiting, headache, bradycardia, puncture site pain, abdominal pain, peripheral edema. 1 Interactions for Abciximab No formal drug interaction studies to date. 1 Specific Drugs Drug Interaction Comments Anticoagulants, oral Potential increased risk of bleeding 1 Use with caution 1 Dextran Increased risk of bleeding 1 Concomitant use contraindicated 1 Dipyridamole Potential increased risk of bleeding 1 Use with caution 1 Heparin Increased risk of bleeding 1 Monitor aPTT or ACT during therapy 1 NSAIAs Potential increased risk of bleeding 1 Use with caution 1 Thrombolytics (e.g., reteplase) Increased risk of major bleeding 1 Weigh risk against anticipated benefit of concomitant therapy 1 Ticlopidine Potential increased risk of bleeding 1 Use with caution 1 Abciximab Pharmacokinetics Absorption Onset Maximal inhibition of platelet aggregation occurs within 10 minutes following IV administration. 1 Duration Bleeding time returns to 12 minutes within 12 24 hours following discontinuance of infusion. 1 Platelet function generally recovers within 48 hours. 1 Distribution Extent Not known whether abciximab is distributed into breast milk or is absorbed systemically after ingestion. 1 Elimination Half-life Initial half-life is> <10 minutes; second phase half-life is about 30 minutes. 1 Abciximab remains in circulation for 15 days in a platelet-bound state. 1 Stability Storage Parenteral Injection 2 8 C. 1 Do not freeze. 1 Compatibility For information on systemic interactions resulting from concomitant use, see Interactions. Parenteral No incompatibilities observed with glass bottles, PVC bags, or IV administration sets. 1 Solution Compatibility 1 No incompatibilities observed with IV fluids. 1 Compatible Dextrose 5% Sodium chloride 0.9% Drug Compatibility No incompatibilities observed with commonly used cardiovascular drugs. 1 Nevertheless, administer abciximab in separate IV line whenever possible; do not mix with other drugs. 1 Y-Site CompatibilityHID Compatible Adenosine 111 Atropine sulfate 111 Bivalirudin Diphenhydramine HCl 111 Fentanyl citrate 111 Metoprolol tartrate 111 Midazolam HCl 111 Actions Fab fragment of chimeric human-murine monoclonal immunoglobulin antibody 7E3. 1 2 3 4 5 6 Binds selectively to platelet GP IIb/IIIa receptors and reversibly inhibits platelet aggregation (by preventing binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa receptors). 1 2 4 5 Advice to Patients Risk of serious bleeding or hemorrhage. 1 4 5 9 Importance of close laboratory monitoring. 1 Importance of informing clinicians of existing or contemplated therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as any concomitant illnesses (e.g., cardiovascular disease). 1 Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed. 1 Importance of advising patients of other important precautionary information. 1 (See Cautions.) Preparations Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details. Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations. Abciximab Routes Dosage Forms Strengths Brand Names Manufacturer Parenteral Injection, for IV use 2 mg/mL (10 mg) ReoPro Lilly AHFS DI Essentials. Copyright 2017, Selected Revisions September 18, 2017. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814. Use is not currently included in the labeling approved by the US Food and Drug Administration. References 1. Eli Lilly and Company. ReoPro (abciximab) injection for intravenous administration prescribing information. Indianapolis, IN; 2005 Jun. 3. 2. Topol EJ, Califf RM, Weisman HF et al. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet . 1994; 343:881-5. [PubMed 7908357] 3. Simoons ML, de Boer MJ, van den Brand MJ et al. Randomized trial of GpIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation . 1994; 89:596-603. [PubMed 7508826] 4. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med . 1994; 330: 956-61. 5. Anon. Centocor will begin shipping Reopro to Lilly in early January: Reopro is the first GpIIbIIIa antagonist for PTCA patients at high risk for ischemic complications. F-D-C Rep . 1995 Jan:16-7. 6. Tcheng JE, Ellis SG, George BS et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation . 1994; 90:1757-64. [PubMed 7923659] 7. Eli Lilly and Company, Indianapolis, IN: Personal communication. 8. Ellis SG, Tcheng JE, Navetta FI et al. Safety and antiplatelet effect of murine monoclonal antibody 7E3Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. Cor Art Dis . 1993; 4:167-75. 9. Eli Lilly and Company, Indianapolis, IN: Personal communication. 10. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med . 1997; 336:1689-96. [PubMed 9182212] 11. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet . 1997; 349:1429-35. [PubMed 9164316] 12. Kleiman NS. A risk-benefit assessment of abciximab in angioplasty. Drug Saf . 1999; 20:43-57. [PubMed 9935276] 13. Detre KM, Holmes DR Jr, Holubkov R et al. Incidence and consequences of periprocedural occlusion: the 1985 1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation . 1990; 82:739-50. [PubMed 2394000] 14. Lincoff AM. Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization. Am J Cardiol . 1998; 82:36P-42P. [PubMed 9809890] 15. Alexander JH, Harrington RA. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A, and PURSUIT. Drugs . 1998; 56:965-76. [PubMed 9878986] 16. White H. Unmet therapeutic needs in the management of acute ischemia. Am J Cardiol . 1997; 80(Suppl 4A):2b-10b. [PubMed 9291240] 17. Tcheng JE. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol . 1996; 78(Suppl 3A):35-40. [PubMed 8751845] 19. Reviewers comments (personal observations) on eptifibatide. 20. Sebastian M, Makkar R. Glycoprotein IIb/IIIa receptor antagonists: clinical pharmacology in cardiovascular diseases of aging. Drugs & Aging . 1999; 15:207-18. 21. Foster RH, Wiseman LR. Abciximab: an updated review of its use in ischaemic heart disease. Drugs . 1998; 56:629-65. [PubMed 9806109] 22. Anon. Randomised placebo-controlled trial of effect of eptifibatide on complication of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet . 1997; 349:1422-8. [PubMed 9164315] 23. Tcheng JE. Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Am J Cardiol . 1997; 80(Suppl 4A):21B-8B. [PubMed 9291242] 25. Agency for Health Care Policy and Research. Diagnosing and managing unstable angina. 1994. (AHCPR publication no. 94-0603) 27. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ . 1994; 308:81-106. [PubMed 8298418] 28. Cairns JA, Gent M, Singer J et al. Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial. N Engl J Med . 1985; 313:1369-75. [PubMed 3903504] 29. Lewis HD, Davies JW, Archibald DG et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med . 1983; 309:396-403. [PubMed 6135989] 30. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet . 1990; 336:827-30. [PubMed 1976875] 31. Théroux P, Waters D, Qiu S et al. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation . 1993; 88(5 Pt 1):2045-8. [PubMed 8222097] 32. Théroux P, Ouimet H, McCans J et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med . 1988; 319:1105-11. [PubMed 3050522] 33. Théroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation . 1998; 97:1195-1206. [PubMed 9537346] 34. Tonkin AM, Aroney CN. Guidelines for managing patients with unstable angina: rating the evidence and rationale for treatment. Med J Aust . 1997; 16:644-7. 35. Cohen M, Demers C, Gurfinkel EP et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med . 1997; 337: 447-52. [PubMed 9250846] 36. Armstrong PW. Heparin in acute coronary disease-requiem for a heavyweight? N Engl J Med . 1997; 337:492-4. (IDIS 389821) 37. Swahn E, Wallentin L for the FRISC study group. Low-molecular weight heparin (fragmin) during instability in coronary artery disease (FRISC). Am J Cardiol . 1997; 80(Suppl. 5A):25E-9E. [PubMed 9296466] 38. Scarborough RM, Kleiman NS, Phillips DR. Platelet glycoprotein IIb/IIIa antagonists: what are the relevant issues concerning their pharmacology and clinical use? Circulation . 1999; 100:437-44. 39. Théroux P. Antiplatelet therapy: do the new platelet inhibitors add significantly to the clinical benefits of aspirin? Am Heart J . 1997; 134:S62-70. 40. Cohen M, Adams PC, Gareth P et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: Primary end points analysis for the ATACS trial. Circulation . 1994; 89:81-8. [PubMed 8281698] 41. Oler A, Whooley MA, Oler J et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis. JAMA . 1996; 276:811-5. [PubMed 8769591] 43. Topol EJ. Targeted approaches to thrombus formation: an end to the shotgun approach. Clin Cardiol . 1997; 20(Suppl I):I-22-6. 44. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med . 1995; 332:1553-9. [PubMed 7739710] 45. Tcheng JE, Harrington RA, Kottke-Marchant K et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrilin in elective coronary intervention. Circulation . 1995; 91:2151-7. [PubMed 7697843] 46. Cor Therapeutics, South San Francisco, CA, and Key Pharmaceuticals, Kenilworth, NJ: Personal communication on eptifibatide. 47. Madan M, Berkowitz SD, Tcheng JE. Glycoprotein IIb/IIIa integrin blockade. Circulation . 1998; 98:2629-35. [PubMed 9843473] 48. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation . 1997; 96:1445-53. [PubMed 9315530] 49. Adgey AAJ. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Am Heart J . 1998; 135:S43-55. 50. Dobesh PP, Latham KA. Advancing the battle against ischemic syndromes: a focus on the GP-IIb/IIIa inhibitors. Pharmacotherapy . 1998; 18:663-85. [PubMed 9692642] 51. Kong DF, Califf Rm, Miller DP et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ishemic heart disease. Circulation . 1998; 98:2829-35. [PubMed 9860783] 52. Vorchheimer DA, Badimon JJ, Fuster V. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease. JAMA . 1999; 281:1407-14. [PubMed 10217057] 53. Giugliano RP, Hyatt RR. Thrombocytopenia with GP IIb/IIIa inhibitors: a meta-analysis. J Am Coll Cardiol . 1998; 31(Suppl 2A):185A. 54. Ferguson JJ, Kereiakes DJ, Adgey AAJ et al. Safe use of platelet GP IIb/IIIa inhibitors. Am Heart J . 1998; 135:S77-89. 55. Quinn M, Fitzgerald DJ. Long-term administration of glycoprotein IIb/IIIa antagonists. Am Heart J . 1998; 135:S113-8. [PubMed 9588390] 56. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb/IIIa blockers. Lancet . 1999; 353:227-31. [PubMed 9923894] 57. Key Pharmaceuticals. Integrelin (eptifibatide) injection prescribing information. Kenilworth, NJ; 1998 May. 59. Merck & Co. Aggrastat (tirofiban hydrochloride) injection premixed and injection prescribing information. West Point, PA; 1999 Jul. 60. Reviewers comments (personal observations) on tirofiban. 61. Merck & Co., West Point, PA: Personal communication on tirofiban. 62. Peerlinck, De Lepeleire I, Goldberg M et al. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation . 1993; 88:1512-7. [PubMed 8403299] 63. Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol . 1997; 80(Suppl 4A):11b-20b. [PubMed 9291241] 64. Key Pharmaceuticals. Integrilin (eptifibatide) product monograph. Kenilworth, NJ; 1998 Aug. 65. Le Breton H, Plow EF, Topol EJ et al. Role of platelets in restenosis after percutaneous coronary revascularization. J Am Coll Cardiol . 1996; 28:1643-51. [PubMed 8962547] 66. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med . 1998; 339:436-43. [PubMed 9705684] 67. Kereiakes DJ, Kleiman NS, Ambrose J et al. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol . 1996; 27:536-42. [PubMed 8606262] 68. Ferguson JJ, Waly HM, Wilson JM. Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition. Am Heart J . 1998; 135:S35-42. [PubMed 9539494] 69. Harrington RA. Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute coronary syndromes. Am J Cardiol . 1997; 80(Suppl 4A):34b-8b. [PubMed 9291244] 70. Merck & Co. Product information form for American hospital formulary service: Aggrastat (tirofiban hydrochloride). West Point, PA; 1998. 72. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med . 1995; 332:1553-9. [PubMed 7739710] 73. Topol EJ, Ferguson JJ, Weisman HF et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin β 3 blockade with percutaneous coronary intervention. JAMA . 1997; 278:479-84. [PubMed 9256222] 74. Lincoff AM, Tcheng JE, Califf RM et al. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one year outcome in the EPILOG trial. Circ . 1999; 99:1951-8. 75. Ghaffari S, kereiakes DJ, Lincoff AM et al. Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional atherectomy. Am J Cardiol . 1998; 82:7-12. [PubMed 9671000] 76. Keriakes D, Lincoff AM, Miller DP et al. Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. Circ . 1998; 97:857-64. 77. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet . 1998; 352:87-92. [PubMed 9672272] 78. Lincoff AM, Califf RM, Moliterno DJ et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet gycoprotein IIb/IIIa receptors. N Engl J Med . 1999; 341:319-27. [PubMed 10423466] 79. Steinhubl SR, Wolski K, Lincoff AM et al. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) trial. Circulation . 2001; 103:1403-9. [PubMed 11245644] 80. Topol EJ, Lincoff AM, Cohen E et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results for a multicentre randomised trial. Lancet . 1999; 354:2019-24. [PubMed 10636365] 81. Eli Lilly and Company. ReoPro (abciximab) injection for intravenous administration prescribing information. Indianapolis, IN; 1998 Feb 12. 82. Akkerhuis KM, Deckers JW, Lincoff AM et al. Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention. JAMA . 2001; 286:78-82. [PubMed 11434830] 87. Brener SJ, Barr LA, Burchenal JE et al. Randomized, placebo-controlled trial of platelet glycoprotein I blockade with primary angioplasty for acute myocardial infarction. Circulation . 1998; 98:734-41. [PubMed 9727542] 88. Neumann FJ, Kastrati A, Schmitt C et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol . 2000; 35: 915-21. [PubMed 10732888] 89. Simoons ML and GUSTO IV-ACS investigators. Effect of glycoprotein IIb/IIIa recptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: the GUSTO IV-ACS randomised trial. Lancet . 2001; 357:1915-24. [PubMed 11425411] 90. Cohen M. Glycoprotein IIb/IIIa receptor blockers in acute coronary syndromes: GUSTO IV-ACS. Lancet . 2001; 357:1899-900. [PubMed 11425405] 91. Antman EM, Fox KM for the International Cardiology Forum. Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: proposed revisions. Am Heart J . 2000; 139:461-75. [PubMed 10689261] 92. Cairns J, Théroux P, Armstrong P et al. Unstable angina Report from a Canadian expert round table. Can J Cardiol . 1996; 12:1279-92. [PubMed 8987969] 93. Armstrong PW. Pursuing progress in acute coronary syndromes. Circulation . 1999; 100:1586-9. [PubMed 10517727] 94. Kaul S, Shah PK. Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin? J Am Coll Cardiol . 2000; 35:1699-702. 99. Goodman S. Enoxaparin and glycoprotein IIb/IIIa inhibition in non-ST-segement-elevation acute coronary syndrome: insights for the INTERACT trial. Am Heart J . 2005; 149:S73-80. [PubMed 16124951] 100. James S, Armstrong P, Califf R et al. Safety and efficacy of abciximab combined with dalteparin in the treatment of acute coronary syndromes. Eur Heart J . 2002; 23:1538-45. [PubMed 12242074] 101. Goodman SG, Fitchett D, Armstrong P et al. Randomized evaluation of the safety and efficacy of enoxaparin versus unfarctionated heparin in high-risk patients with non-ST-sgement elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation . 2003; 107:238-44. [PubMed 12538422] 103. Lansky AJ, Hochman JS, Ward PA et al. Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professional from the American Heart Association. Circulation . 2005; 111:940-3. [PubMed 15687113] 104. Kastrati A, Mehilli J, Neumann FJ et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomzed trial. JAMA . 2006; 295:1531-8. [PubMed 16533938] 105. Moliterno DJ, Yabubov SJ, DiBattiste PM et al. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization with stent placement: the TARGET follow-up study. Lancet . 2002; 360:355-60. [PubMed 12241774] 106. Eagle KA, Guyton RA, Davidoff R et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Available at: . Accessed 2006 Nov 10. 111. Baroletti S, Hartman C, Churchill W. Visual compatibility of abciximab with selected drugs. Am J Health-Sys Pharm 2002; 59:466-7. 991. Anderson JL, Adams CD, Antman EM et al. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation . 2011; 123:e426-579. 994. Levine GN, Bates ER, Blankenship JC et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol . 2011; 58:e44-122. [PubMed 22070834] 995. Hamm CW, Bassand JP, Agewall S et al, for The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST -segment elevation of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J . 2011; 32:2999-3054. [PubMed 21873419] 1016. Eikelboom JW, Hirsh J, Spencer FA et al. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest . 2012; 141(2 Suppl):e89S-119S. 1100. Amsterdam EA, Wenger NK, Brindis RG et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation . 2014; 130:e344-426. [PubMed 25249585] HID. Trissel LA. Handbook on injectable drugs. 13th ed; Bethesda, MD: American Society of Health-System Pharmacists; 2005:3. Next Interactions Print this page Add to My Med List More about abciximab Side Effects During Pregnancy Drug Interactions Support Group 0 Reviews Add your own review/rating Drug class: glycoprotein platelet inhibitors Consumer resources Abciximab Abciximab Intravenous (Advanced Reading) Professional resources Abciximab (Wolters Kluwer) Other brands: ReoPro Related treatment guides High Risk Percutaneous Transluminal Angioplasty> ]} FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Drug Status Rx Availability Prescription only C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Drug Class Glycoprotein platelet inhibitors Related Drugs High Risk Percutaneous Transluminal Angioplasty ReoPro , More... Abciximab Rating No Reviews - Be the first! No Reviews - Be the first! Not Rated - Be the first!} } decent
tangled up Abciximab a quirky
EmoticonEmoticon